Empowered Patient Podcast

Sally Embrey, Vice President Public Health and Health Tech, DataRobot is applying knowledge from work as an enterprise AI company to attacking the problem of containing and defeating COVID-19. ContagionNET was created to identify leading and lagging indicators of the next COVID-19 hotspot and to help people understand their status, risk and ability to spread the disease. Combining science, testing data and AI-based technology, models have been created and used by NIH, HHS, FDA and other partners to better allocate resources, recruit for vaccine trials, and make more accurate long-term forecasts. @ContagionNET #DataRobot #COVID19 #pandemic #NIH #PopulationHealth #AI #VaccineTrials #COVIDHotSpots DataRobot.com Download the transcript here

Dr. Stephen Brannan, Chief Medical Officer, Karuna Therapeutics discusses the need for creating and delivering transformative medicines for people living with psychiatric and neurological conditions particularly schizophrenia. Pairing the muscarinic agonist with a pan-cholinergic antagonist that does not cross into the central nervous system, KarXT is mitigating the peripheral side effects like weight gain and sedation but still retaining the benefits from muscarinic agonist. @KarunaPharma $KRTX #NeuroTwitter #CNS #schizophrenia #schizoprenia #Neuroscience KarunaTX.com Download the transcript here

Jonathan Rigby, CEO, Revolo Biotherapeutics discusses the company's revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, with less frequent chronic dosing and without suppression of the immune system. A goal that others have not been able to reach. Revolo Bio's platform drug candidates '1805 and '1104 are in development for rheumatoid arthritis, uveitis, eosinophilic esophagitis and allergic diseases. @RevoloBio #AutoimmuneDisease #AllergicDisease #RheumatoidArthritis #Uveitis #EosinophilicEsophagitis RevoloBio.com Download the transcript here

Anthony Comfort, VP Product Management, VisiQuate reflects on how far science and technology have come in helping monitor the health of diabetics with a new understanding of chemical changes in the body as well as cognitive and behavioral aspects. With the change from manual monitoring blood glucose readings to continuous data streaming in real time, patients and endocrinologists are able to stitch together data from a variety of sources to come up with personalized plans. Applying AI-enabled models and working with payers, providers and medical device companies, the goal is to optimize outcomes for patients and reduce costs. @VisiQuate #DigitalTransformation #AI #COVID19 #DiabetesManagement #DigitalHealth #precisionmedicine VisiQuate.com Download the transcript here  

Derek Maetzold, President and CEO, Castle Biosciences is harnessing the power of genomics to understand the biology of skin cancer. Castle has developed genomic tests to determine how aggressive melanoma and squamous cell carcinoma are in order to better inform dermatologist and patients about intervention decisions. With both diagnostic and prognostic tests and assist from artificial intelligence machine learning-based algorithms, calculations are made for assessing the risk of developing metastatic disease for each individual patient. @CastleBio #SkinCancer #Melanoma #SquamousCellCarcinoma #GenomicTesting #Dermatology CastleBiosciences.com Download the transcript here

Len May, CEO, EndoCanna Health is aggressively exploring the genes that are associated with metabolism of cannabinoids and aiming for a better understanding of the endocannabinoid system to guide the use of cannabis for a wide range of conditions and disorders. With an eye to the complexity of the cannabis plant, EndoCanna has developed a test to determine an individual's genotype and endocompatibility to identify possible drug interactions, adverse effects and benefits of an optimal ratio of cannabinoids and terpenes endo-aligned dosage. #cannabis #EndocannabinoidSystem #endocompatibility #terpenes #cannabinoids #THC #CBD EndoDNA.com Download the transcript

Evan Levine, Co-Founder and CEO, PsyBio Therapeutics is pursuing a paradigm shift in the treatment of mental illness and other neurological disorders by using psychedelics and hallucinogenics. PsyBio biosynthesizes psilocybin and other psychoactive drugs from different plants  and fungi from genetically-modified bacteria. Under the influence of an anxiogenic molecule in a controlled setting, early clinical trials are showing a change in consciousness and rewiring of the brain to be able to address issues such as depression, anxiety, PTSD and substance abuse. #Psychedelics #Psilocybin #Hallucinogenics #neuropsychiatricdisorders #tryptamines #PTSD #depression PsyBioLife.com Download the transcript here

Michael Tkach, Chief Operating Officer and Chief Behavioral Health Officer, Affinity describes a variety of models for large-scale population healthcare management for Return to Work/Stay at Work in this time of COVID-19. With continuous monitoring, testing and data analysis, risk assessment is being used to keep companies aware of adherence to guidelines and regulations and the physical and mental health of their employees. In addition, Affinity is rolling out pop-up COVID Clinics in business settings and in communities with limited healthcare options to provide testing and COVID related information. @AffinityRTW #MentalHealthMonday #COVID19Testing #workplacetesting #returntowork #WorkplaceMentalHealth #humanresources #mentalhealth AffinityReturntoWork.com/rtw Download the transcript here

Dr. Greg Rippon, Vice President and Chief Medical Partner of Neurology, Genentech shines light on SMA, spinal muscular atrophy, a severe inherited progressive neuromuscular disease and one of the most common rare diseases affecting babies. With the introduction of Evrysdi to the treatment options for SMA, an oral treatment is being tested to increase the production of the functional survival motor neuron protein and thus benefit patients in their motor functioning. @genentech #genentech #SMA #SpinalMuscularAtrophy #Evrysdi #raredisease GENE.com Download the transcript here.

Dr. Sudarshan Hebbar, Chief Medical Officer, CalciMedica talks about developing drugs that are focused on targeting CRAC channels, calcium release activated calcium channels, in order to modulate these channels to help treat diseases that have a significant inflammatory component.  Initially developed drugs for acute pancreatitis targeting both the pancreas and the lung. Now conducting large trial in patients with severe and critical COVID-19 as many of the mechanisms that are shared in the development of lung disease with COVID-19 are shared with acute pancreatitis. Strong evidence that their drug Auxora  might be effective for a variety of disorders that cause lung injury. @CalciMedicaInc #COVID19 #CriticalCare #inflammatorydiseases #pancreatitis #CRACChannelinhibitors CalciMedica.com Download the transcript here